Research Paper Volume 14, Issue 7 pp 3276—3292
An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis
- 1 Department of Burn and Plastic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- 2 Department of General Surgery, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, Anhui, China
- 3 Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
- 4 Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, Beijing, China
- 5 Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
- 6 College of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu, China
Received: August 27, 2021 Accepted: April 2, 2022 Published: April 12, 2022
https://doi.org/10.18632/aging.204012How to Cite
Copyright: © 2022 Xie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and is often associated with a poor prognosis. The main reason for this poor prognosis is that inconspicuous early symptoms lead to delayed diagnosis. Treatment options for advanced HCC remain limited and ineffective. In this context, the exploration of the immune microenvironment in HCC becomes attractive. In this study, we divided HCC into immune cell and non-immune cell subtypes, by single-cell sequencing analysis of GEO dataset GSE146115. We found differentially expressed genes in the two subtypes, which we used to construct a prognostic model for HCC through Cox and Lasso regressions. Our prognostic model can accurately evaluate the prognosis of HCC patients, and provide a reference for the design of immunotherapy for HCC.